| Diabetic kidney disease is a major risk of end-stage kidney failure and is associated with great morbidity and mortality,
predominantly with accelerated cardiovascular disease. Current investigations have focused on the optimization of
renin-angiotensin system blockade in patients with diabetic kidney disease using combinations of drugs that target this
pathway, however some studies have focused on the potential of novel treatments that either target various pathways
up-regulated by hyperglycemia or other targets believed to promote progression of diabetic kidney disease such as
endothelin system, inflammation and vitamin D receptors. So far, a strong body of evidence supports vitamin D as
a negative regulator of the circulating and local tissue renin-angiotensin system, while the renin-angiotensin system
have a critical role in the physiology of sodium and volume homeostasis. The results of oral vitamin D therapy in type
2 diabetic patients are encouraging. However, more prospective interventional studies with larger duration and control
of confounders are suggested |